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Background-—Atrial fibrillation (AF) is associated with increased risk of hospitalization. Little is known about the impact of AF on
utilization of noninpatient health care or about sex or race differences in AF-related utilization. We examined rates of inpatient and
outpatient utilization by AF status in the Atherosclerosis Risk in Communities study.
Methods and Results-—Participants with incident AF enrolled in fee-for-service Medicare for at least 12 continuous months
between 1991 and 2009 (n=932) were matched on age, sex, race and field center with up to 3 participants without AF (n=2729).
Healthcare utilization was ascertained from Medicare claims and classified by primary International Classification of Diseases,
ninth revision code. The average annual numbers of days hospitalized were 13.2 (95% CI 11.6 to 15.0) and 2.8 (95% CI 2.5 to 3.1)
for those with and without AF, respectively. The corresponding numbers of annual outpatient claims were 53.3 (95% CI 50.5 to
56.3) and 22.9 (95% CI 22.1 to 23.8) for those with and without AF, respectively. Most utilization among AF patients was
attributable to non-AF conditions. The adjusted rate ratio for annual days hospitalized for other cardiovascular disease–related
reasons was 4.58 (95% CI: 3.41 to 6.16) for those with AF versus those without AF. The association between AF and healthcare
utilization was similar among men and women and among white and black participants.
Conclusions-—Participants with AF had considerably greater healthcare utilization, and the difference in utilization for other
cardiovascular disease–related reasons was substantial. In addition to rate or rhythm treatment, AF management should focus on
the accompanying cardiovascular comorbidities. ( J Am Heart Assoc. 2014;3:e001006 doi: 10.1161/JAHA.114.001006)
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I n the United States, the most recent annual national datareported 479 000 hospitalizations with atrial fibrillation (AF)
as the primary diagnosis.1 Hospitalizations with AF as the
primary diagnosis increased by 34% from 1996 to 2001.2 The
outpatient burden is also high, with 5 million physician office
visits, 276 000 emergency department visits, and 234 000
hospital outpatient visits attributed to AF in the United States in
2001.3 AF patients have many comorbidities: More than half of
AF diagnoses can be explained by having at least 1 nonoptimal
risk factor.4 Furthermore, AF is a cause of stroke5,6 and is
strongly associated with other cardiovascular morbidity, includ-
ing heart failure (HF)7,8 and acute myocardial infarction,9,10 and
mortality.11 Healthcare utilization among AF patients is signif-
icant from both economic and clinical perspectives; however, it
is unknown whether this utilization is related directly to AF or to
comorbidities, which are common among AF patients.
Administrative claims data indicate that, compared with
age- and sex-matched beneficiaries without AF, those with AF
had twice as many hospitalizations during the 12-month
period following initial AF diagnosis.12 A more granular
analysis reported that the primary reasons for first hospital-
ization following AF diagnosis were AF (26.4%), HF (21.7%),
coronary or peripheral arterial causes (21.6%), and thrombo-
embolic events (10.5%).13 In addition to hospitalizations, there
is evidence of overall increased utilization among patients
with AF compared with matched controls.14
The overall clinical burden of AF is substantial, and sex and
race disparities in access to and quality of health care among
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AF patients have been documented15–18; however, it is
unknown whether the association between AF and healthcare
utilization is similar among men and women and among white
and black patients.
Given the substantial and increasing burden of AF on
healthcare utilization, the limited knowledge about inpatient
and noninpatient utilization, and the lack of sex- and race-
specific data, we sought to improve understanding of how AF
patients utilize health care and to provide data that can be used
to allocate adequate resources for the care of AF patients.
Specifically, we compared healthcare utilization (inpatient or
outpatient) and primary reason (AF related, other cardiovas-
cular disease [CVD] related, and non-CVD related) for seeking
medical care among Atherosclerosis Risk in Communities
(ARIC) study participants with AF and those without AF. We
also described differences in utilization by sex and race.
Methods
Data Sources
The ARIC study is a population-based prospective study of
CVD in a cohort of 15 792 predominantly black and white
participants aged 45 to 64 years at enrollment in 1987–
1989.19 Participants were sampled from 4 US communities:
Forsyth County, North Carolina; Jackson, Mississippi; the
northwestern suburbs of Minneapolis, Minnesota; and Wash-
ington County, Maryland. Additional participant contact
occurred through 4 follow-up clinic visits and through annual
telephone contact to obtain information regarding all hospi-
talizations and vital status, details of which have been
reported previously.20
The ARIC study has an interagency agreement with the
Centers for Medicare and Medicaid Services (CMS) to obtain
Medicare data for ARIC cohort participants. Participants are
matched on social security number, sex, and date of birth. The
finder file included 15 738 ARIC participants, of which 14 530
(92.3%) were matched successfully and linked to CMS
Medicare claims. Data for participants who matched success-
fully were linked to inpatient, outpatient, and carrier files. The
Medicare Provider Analysis and Review (MedPAR) file contains
claims for inpatient services covered under Medicare Part A.
The outpatient files contain claims for services covered under
Medicare Part B, including institutional claims (outpatient file)
for outpatient services and noninstitutional physician claims
(carrier file). CMS claims for inpatient and outpatient services
have been available for research since 1991.
Study Sample
For this analysis, ARIC participants enrolled in fee-for-service
(FFS) Medicare, both Parts A and B, for at least 12 continuous
months between January 1, 1991, and December 31, 2009,
were eligible for inclusion; for participants with multiple FFS
enrollment periods (n=647), only the first was included
(Figure 1). Medicare FFS enrollment was necessary because
Medicare Advantage insurance plans are not required to
submit claims for beneficiaries. In addition, those enrolled in
only Part A (FFS) do not have claims data for Part B services
(eg, outpatient and physician visits). Participants whose race
was neither white nor black and nonwhites from the
Minneapolis and Washington County field centers were
excluded because of small numbers. Both active ARIC cohort
follow-up and surveillance of CMS data were used to identify
and exclude all participants with prevalent AF. As such, based
on initial ARIC study examination, participants with missing or
unreadable ECG and those with prevalent AF on the baseline
ECG were excluded. We were interested in incident AF;
therefore, using all available information from ARIC and CMS,
we excluded participants diagnosed with AF prior to January 1,
1992 (CMS data were available for research beginning January
1, 1991), participants with AF diagnosed prior to FFS
enrollment or during the first year of FFS enrollment, and
participants who stopped participating in ARIC follow-up.
Participants enrolled in Medicare because of disability or
certain covered medical conditions were not included in the
study unless they met study eligibility criteria after becoming
age eligible (aged ≥65 years). Participants who died on the
date of AF diagnosis were excluded.
Participants with incident AF diagnosed based on Medicare
data during their initial FFS enrollment period were matched
with up to 3 ARIC participants without AF based on age
(within 2 years), sex, race, and field center; matching was
used to account for strong confounders and was performed
with the SAS macro gmatch, developed at the Mayo Clinic.21
Three matches were found for 93% of participants with AF. Of
the 3737 participants, 3661 (932 with AF and 2729 without
AF) had complete covariate information and composed our
final sample. Each field center’s institutional review board
approved the study, and all participants provided informed
consent.
Definition of Atrial Fibrillation
Incident AF cases were ascertained through MedPAR and
outpatient CMS claims. Incident AF was defined as an AF
discharge diagnosis, with International Classification of Dis-
eases, ninth revision (ICD-9) code 427.3x, in any position, on
a single short-stay inpatient (MedPAR) claim or on 2
outpatient claims within 7 to 365 days. A minimum of 2
outpatient claims at least 7 days apart were required to
reduce the likelihood of including “rule out” diagnoses and to
improve the algorithm specificity.22,23 The AF incidence date
was defined as the discharge date for a MedPAR short-stay
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claim or the date of the second qualifying outpatient claim,
whichever occurred earliest. AF following cardiac operative
procedures occurs frequently.24 Accordingly, AF diagnosis
occurring simultaneously with cardiac revascularization (ICD-9
code 36.x) or other cardiac surgery involving heart valves or
septa (ICD-9 code 35.x) during the index hospitalization
without a subsequent AF diagnosis was not included.
Definition of Healthcare Utilization
Healthcare utilization was ascertained from short-stay inpa-
tient (MedPAR files) and outpatient (outpatient and carrier
files) Medicare claims. Each claim was classified based on the
primary discharge diagnosis code as AF related (ICD-9 code
427.3x), other CVD related (ICD-9 codes 390.x to 459.x)
excluding AF, and non-CVD related (all other valid ICD-9
codes). Claims with an invalid or missing primary diagnosis
code were classified based on the first-listed usable diagnosis
code. Length of hospitalization was taken into account for
inpatient healthcare utilization by calculating length of stay.
Multiple claims for the same date of service with identical
diagnosis codes were considered one claim.
Assessment of Covariates
During the baseline ARIC study examination, standardized
methods were used to collect data on age, race, sex,
educational achievement, cigarette smoking, ethanol
Figure 1. Derivation of study sample. AF indicates atrial fibrillation; ARIC, Atheroscle-
rosis Risk in Communities; FFS, fee-for-service.
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consumption, height, weight, blood pressure, antihypertensive
medication use, diabetes mellitus, total cholesterol, low-
density lipoprotein cholesterol, high-density lipoprotein cho-
lesterol, triglycerides, creatinine-based estimated glomerular
filtration rate, forced expiratory volume in 1 second, previous
myocardial infarction, HF, or coronary heart disease.19 An
ECG Cornell voltage >28 mm in men or >22 mm in women
was considered evidence of left ventricular hypertrophy.25
Data on these covariates were updated during additional ARIC
study examinations. Creatinine-based estimated glomerular
filtration rate was measured at visits 1, 2, and 4, whereas
forced expiratory volume in 1 second was considered only at
visit 1. For this analysis, the behavioral and clinical charac-
teristics were updated to reflect the information from the
closest study examination preceding AF diagnosis (for those
with incident AF) or date of matching (for those without
incident AF).
Statistical Analysis
Person-years of follow-up were calculated as the date of
incident AF diagnosis or the matching date until the date of
disenrollment in FFS Medicare, death, or December 31, 2009,
whichever occurred earliest. The annualized rate of inpatient
(MedPAR) utilization was calculated by dividing the total
number of days hospitalized by the corresponding person-
years of follow-up, which can be interpreted as the average
annual number of days hospitalized per person. The annual-
ized rate of outpatient utilization was calculated by dividing
the total number of unique claims per date of service by the
corresponding person-years of follow-up. Negative binomial
regression models were used to calculate rates and rate ratios
of inpatient and outpatient utilization, comparing those with
and without AF; models include an offset of log follow-up time
to account for differential follow-up. Covariate data were
updated to reflect the closest ARIC examination preceding AF
diagnosis or the matched reference date for those without AF.
Participants with missing covariate data were excluded
(n=32). Sex- and race-specific rates of healthcare utilization
(inpatient and outpatient) were also calculated. The rate of
utilization, classified based on the primary diagnosis code as
AF, other CVD, or non-CVD related, was calculated with the
same approach as described above for inpatient and outpa-
tient utilization. Covariates with a statistically significant
univariable association were retained in multivariable models.
A descriptive analysis, restricted to hospitalizations for other
CVD–related reasons and stratified by AF status, was
performed to identify the primary reasons for and rates of
hospitalization.
Prespecified 2-way multiplicative interactions of healthcare
utilization (inpatient [MedPAR] and outpatient considered
separately) with sex and race were examined. A sensitivity
analysis to assess secular trends in the association of AF with
healthcare utilization was conducted by including year
(defined as year of AF diagnosis for those with incident AF
or year of matching for those without incident AF) modeled in
quartiles (1992–1999, 2000–2003, 2004–2006, and 2007–
2009) and an interaction term between year and AF status in
a negative binomial regression model. A sensitivity analysis,
restricted to matched AF and non-AF participants with similar
propensity scores, was performed. A logistic regression model
was used to determine the probability of AF based on known
risk factors for AF development. Suitable propensity score
matches were identified within previously matched AF and
non-AF participants and defined as a caliper width ≤0.02,
which corresponds to 25% of the standard deviation, as
recommended by Rosenbaum and Rubin.26 All statistical
analyses were performed with SAS version 9.2.
Results
Of the original 15 792 ARIC participants, our final analytic
sample included 3661 participants (932 with AF and 2729
without AF) who were enrolled in FFS Medicare for at least 12
continuous months between January 1, 1991, and December
31, 2009. Characteristics of the study sample, stratified by AF
status and updated to reflect the closest ARIC study
examination values preceding AF diagnosis or matching, are
shown in Table 1. The mean age at AF diagnosis or matching
was 73.3 years (SD 4.7 years). Women composed 45% and
black participants composed nearly 15% of the study sample.
Participants with AF were more likely to be current smokers
and to have higher body mass indices, hypertension, diabetes
mellitus, left ventricular hypertrophy, HF, and coronary heart
disease and lower creatinine-based estimated glomerular
filtration rates and forced expiratory volume in 1 second.
During a mean follow-up of 4.1 years, there were 2604
hospitalizations among the 932 participants with AF; the
median length of stay was 5 days (interquartile range: 3 to 9
days). Among the 2729 without AF, there were 2965
hospitalizations during a mean follow-up of 4.2 years; the
median length of stay was 5 days (interquartile range: 3 to 8
days). The unadjusted mean days hospitalized per year were
13.2 (95% CI 11.6 to 15.0) and 2.8 (95% CI 2.5 to 3.1) for
participants with and without AF, respectively (Table 2). After
accounting for matching criteria, the number of days hospi-
talized per year was 4.85 (95% CI 4.03 to 5.84) times higher
among participants with AF than in those who remained free
of AF. After adjustment for potential confounders, the rate of
days in the hospital was 3.94 (95% CI 3.29 to 4.73) times
greater among those with AF. Healthcare utilization in the
outpatient setting was higher among participants with AF
compared with those without AF (Table 2). The median
number of claims during follow-up was 122.5 (interquartile
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range: 47 to 232.5) for those with AF and 50 (interquartile
range: 17 to 115) for those without AF, based on unique
claims per date of service. The unadjusted annual rate of
outpatient utilization was 53.3 (95% CI 50.5 to 56.3) and 22.9
(95% CI 22.1 to 23.8) for those with and without AF,
respectively. After accounting for matching criteria and other
potential confounders, the rate ratio for outpatient utilization
remained significantly greater among those with AF compared
with those without AF (rate ratio 2.14, 95% CI 2.00 to 2.29).
The interaction of sex with AF was not significant for
inpatient (MedPAR) (P=0.12) or outpatient (P=0.39) utiliza-
tion. The unadjusted annual rate (mean days hospitalized) of
inpatient (MedPAR) healthcare utilization was highest for
women with AF at 15.7 (95% CI 12.9 to 19.1) and lowest for
women without AF at 2.5 (95% CI 2.2 to 3.0) (Table 3).
Healthcare utilization following AF diagnosis did not differ
significantly between white and black participants for
inpatient (MedPAR) (P-interaction=0.65) or outpatient
(P-interaction=0.13) utilization. Black participants with AF
had the highest unadjusted annual rate of days hospitalized
(rate 17.8, 95% CI 12.0 to 26.3) and outpatient utilization
(rate 53.9, 95% CI 45.5 to 63.9) (Table 4).
Among participants with AF, the unadjusted annual rate of
days hospitalized with AF as the primary diagnosis was 0.5
(95% CI 0.3 to 0.7). The annual rate of days hospitalized for
other CVD-related reasons was 4.2 (95% CI 3.5 to 5.2) among
those with AF and 0.8 (95% CI 0.6 to 0.9) among those
without AF (Table 5). After adjustment for matching criteria
and other potential confounders, the adjusted rate ratio for
days hospitalized per year for other CVD–related reasons was
4.58 (95% CI 3.41 to 6.16) for those with and those without
AF. The magnitude of the difference was smaller for non-CVD–
related hospitalized days (adjusted rate ratio 3.52, 95% CI
Table 1. Characteristics of Participants by AF Status Based
on Closest Atherosclerosis Risk in Communities Study




Age at matching, y 73.54.8 73.34.6
Women 44.3 45.3
Black 13.2 14.1
High school graduate 75.0 77.1 0.20
Current smoker 19.0 13.5 <0.0001
Current drinker 49.4 51.7 0.21
Body mass index, kg/m2 29.35.7 28.35.2 <0.0001
Hypertension 60.0 48.8 <0.0001
Antihypertensive medication 47.8 35.8 <0.0001
Diabetes mellitus 21.0 16.3 0.001
Total cholesterol, mg/dL 199.837.3 203.837.5 0.004
LDL-c, mg/dL 124.034.6 126.634.3 0.05
HDL-c, mg/dL 44.518.1 46.018.6 0.03




FEV1, L 2.80.8 2.90.7 0.04
Left ventricular hypertrophy 3.9 2.1 0.002
Heart failure 10.5 3.7 <0.0001
Coronary heart disease 19.0 9.4 <0.0001
Categorical variables presented as percentages; continuous variables presented as
meanSD. P values comparing the distributions of age, sex, and race are not presented
because these variables were used to match participants without AF to those with AF,
ensuring balance in their distribution. AF indicates atrial fibrillation; eGFRcreat, creatinine-
based estimated glomerular filtration rate; FEV1, forced expiratory volume in 1 second;
HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
Table 2. Association of AF With Inpatient (MedPAR) and
Outpatient Healthcare Utilization Among Atherosclerosis Risk
in Communities Study Participants








10 (0 to 30) 0 (0 to 7)
Unadjusted rate† 13.2 (11.6 to 15. 0) 2.8 (2.5 to 3.1)
Unadjusted rate ratio 4.84 (4.02 to 5.82) Reference
Rate ratio adjusted for
matching criteria‡
4.85 (4.03 to 5.84) Reference
Fully adjusted rate
ratio§




122.5 (47 to 232.5) 50 (17 to 115)
Unadjusted rate† 53.3 (50.5 to 56.3) 22.9 (22.1 to 23.8)
Unadjusted rate ratio 2.34 (2.18 to 2.50) Reference
Rate ratio adjusted for
matching criteria‡
2.33 (2.17 to 2.49) Reference
Fully adjusted rate
ratio§
2.14 (2.00 to 2.29) Reference




‡Adjusted for matching criteria: age (2 years), sex, race, and field center.
§Adjusted for matching criteria and for high school graduate, current smoking, current
drinking, body mass index, hypertension, antihypertensive medication, diabetes mellitus,
creatinine-based estimated glomerular filtration rate, forced expiratory volume in
1 second, and prior heart failure and coronary heart disease.
kOutpatient utilization defined as unique claims per date of service.
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Table 3. Association of AF With Inpatient (MedPAR) and Outpatient Healthcare Utilization Among Atherosclerosis Risk in
Communities Participants Stratified by Sex
Men Women
AF (n=519) No AF (n=1494) AF (n=413) No AF (n=1235)
Follow-up, years (meanSD) 4.23.7 4.03.5 4.03.5 4.43.7
Inpatient (MedPAR) utilization, days
Per person, median (IQR)* 9 (0 to 28) 0 (0 to 7) 10 (0 to 32) 0 (0 to 7)
Unadjusted rate† 11.3 (9.5 to 13.4) 3.1 (2.7 to 3.5) 15.7 (12.9 to 19.1) 2.5 (2.2 to 3.0)
Unadjusted rate ratio 3.80 (2.97 to 4.85) Reference 6.43 (4.87 to 8.50) Reference
Rate ratio adjusted for matching criteria‡ 3.54 (2.77 to 4.52) Reference 6.72 (5.06 to 8.93) Reference
Fully adjusted rate ratio§ 3.42 (2.69 to 4.36) Reference 4.77 (3.59 to 6.35) Reference
Outpatient utilization||
Per person, median (IQR)* 127 (49 to 245) 48 (17 to 113) 111 (40 to 221) 52 (15 to 116)
Unadjusted rate† 53.1 (49.7 to 56.6) 23.9 (22.7 to 25.1) 53.6 (49.0 to 58.7) 21.8 (20.6 to 23.0)
Unadjusted rate ratio 2.24 (2.05 to 2.45) Reference 2.46 (2.21 to 2.74) Reference
Rate ratio adjusted for matching criteria‡ 2.20 (2.01 to 2.40) Reference 2.46 (2.21 to 2.74) Reference
Fully adjusted rate ratio§ 2.06 (1.88 to 2.25) Reference 2.26 (2.03 to 2.51) Reference
AF indicates atrial fibrillation; IQR, interquartile range; MedPAR, Medicare Provider Analysis and Review.
*During follow-up.
†Rate per year.
‡Adjusted for matching criteria: age (within 2 years), sex, race, and field center.
§Adjusted for matching criteria and for high school graduate, current smoking, current drinking, body mass index, hypertension, antihypertensive medication, diabetes mellitus, creatinine-
based estimated glomerular filtration rate, forced expiratory volume in 1 second, and prior heart failure and coronary heart disease.
||Outpatient utilization defined as unique claims per date of service.
Table 4. Association of AF With Inpatient (MedPAR) and Outpatient Healthcare Utilization Among Atherosclerosis Risk in
Communities Participants Stratified by Race
White Black
AF (n=809) No AF (n=2344) AF (n=123) No AF (n=385)
Follow-up, years (meanSD) 4.23.6 4.33.6 3.63.2 4.03.6
Inpatient (MedPAR) utilization, days
Per person, median (IQR)* 10 (0 to 29) 0 (0 to 7) 8 (0 to 37) 0 (0 to 5)
Unadjusted rate† 12.5 (10.9 to 14.3) 2.8 (2.5 to 3.1) 17.8 (12.0 to 26.3) 3.2 (2.3 to 4.5)
Unadjusted rate ratio 4.70 (3.87 to 5.70) Reference 5.64 (3.15 to 10.09) Reference
Rate ratio adjusted for matching criteria‡ 4.70 (3.87 to 5.71) Reference 5.69 (3.17 to 10.23) Reference
Fully adjusted rate ratio§ 3.94 (3.25 to 4.77) Reference 4.69 (2.59 to 8.50) Reference
Outpatient utilizationk
Per person, median (IQR)* 127 (49 to 236) 52.5 (18 to 118) 94 (33 to 176) 37 (8 to 97)
Unadjusted rate† 53.2 (50.3 to 56.3) 23.2 (22.3 to 24.1) 53.9 (45.5 to 63.9) 21.3 (18.8 to 24.0)
Unadjusted rate ratio 2.30 (2.14 to 2.47) Reference 2.55 (2.02 to 3.22) Reference
Rate ratio adjusted for matching criteria‡ 2.29 (2.13 to 2.46) Reference 2.57 (2.03 to 3.25) Reference
Fully adjusted rate ratio§ 2.11 (1.96 to 2.26) Reference 2.37 (1.88 to 2.98) Reference
AF indicates atrial fibrillation; IQR, interquartile range; MedPAR, Medicare Provider Analysis and Review.
*During follow-up.
†Rate per year.
‡Adjusted for matching criteria: age (within 2 years), sex, race, and field center.
§Adjusted for matching criteria and for high school graduate, current smoking, current drinking, body mass index, hypertension, antihypertensive medication, diabetes mellitus, creatinine-
based estimated glomerular filtration rate, forced expiratory volume in 1 second, and prior heart failure and coronary heart disease.
kOutpatient utilization defined as unique claims per date of service.
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2.87 to 4.31). The unadjusted annual rate of days hospitalized
for non-CVD–related reasons was 8.2 (95% CI 7.1 to 9.5) for
those with AF and 2.0 (95% CI 1.8 to 2.3) for those without
AF. A descriptive analysis revealed that HF was the leading
cause of non-AF CVD-related hospitalizations for those with
AF (51.6 per 1000 person-years). Among those without AF,
the rate of non-AF CVD-related hospitalization was greatest
for cerebrovascular disease (17.4 per 1000 person-years)
(Table 6). Outpatient utilization followed a similar pattern; the
magnitude of the difference between those with AF and those
without AF was greatest for other CVD–related reasons
(adjusted rate ratio 2.46, 95% CI 2.24 to 2.70).
A sensitivity analysis of secular trends in the association of
AF and healthcare utilization revealed statistically significant
effect modification of the association by year of matching for
inpatient (MedPAR) (P=0.03) and outpatient (P=0.01) utiliza-
tion. The fully adjusted rate ratios for those with and those
without AF increased over the study period (Figure 2). In
1992–1999, the multivariable adjusted rate ratio for inpatient
(MedPAR) utilization was 2.73 (95% CI 1.96 to 2.09); in 2007–
2009, it was 7.00 (95% CI 4.04 to 12.12). The trend in
outpatient utilization was similar but with a less sizable
increase. The multivariable adjusted rate ratios in 1992–1999
and 2007–2009 were 1.82 (95% CI 1.59 to 2.09) and 2.53
(95% CI 2.22 to 2.89), respectively. The observed trend
remained essentially the same after including an age9period
term in the model.
In a sensitivity analysis restricted to matched AF and non-AF
participants with similar propensity scores, the primary results
were corroborated. Among the 354 ARIC participants with AF
Table 5. Primary Reason for Inpatient (MedPAR) and Outpatient Healthcare Utilization Among Atherosclerosis Risk in Community
Study Participants Stratified by AF Status
AF (n=932) No AF (n=2729) Adjusted Rate Ratio*
Inpatient (MedPAR) utilization, days
Unadjusted rates†
AF related 0.5 (0.3 to 0.7) — —
Other CVD related 4.2 (3.5 to 5.2) 0.8 (0.6 to 0.9) 4.58 (3.41 to 6.16)
Non-CVD related 8.2 (7.1 to 9.5) 2.0 (1.8 to 2.3) 3.52 (2.87 to 4.31)
Outpatient utilization‡
Unadjusted rates†
AF related 4.8 (4.3 to 5.4) 0.01 (0.01 to 0.02) —
Other CVD related 9.0 (8.4 to 9.7) 3.3 (3.1 to 3.5) 2.46 (2.24 to 2.70)
Non-CVD related 38.8 (36.7 to 41.1) 19.4 (18.7 to 20.2) 1.85 (1.72 to 1.99)
AF indicates atrial fibrillation; CVD, cardiovascular disease; MedPAR, Medicare Provider Analysis and Review.
*Adjusted for matching criteria and for high school graduate, current smoking, current drinking, body mass index, hypertension, antihypertensive medication, diabetes mellitus, creatinine-
based estimated glomerular filtration rate, forced expiratory volume in 1 second, and prior heart failure and coronary heart disease.
†Rates are days per year for inpatient (MedPAR) data and number of unique claims per date of service per year for outpatient claims.
‡Outpatient utilization defined as unique claims per date of service.
Table 6. Descriptive Analysis of the Primary Diagnosis Codes for Non-AF CVD-Related Hospitalizations Stratified by AF Status
AF (n=932) No AF (n=2729)
Number Rate* Number Rate
Total person-years of follow-up 3818 11 516
Total non-AF CVD-related hospitalizations 804 210.6 723 62.8
Hypertensive disease (401 to 405) 40 10.5 27 2.3
Myocardial infarction (410) 74 19.4 81 7.0
Coronary atherosclerosis, native vessel (414.01) 97 25.4 117 10.2
Heart failure (428) 197 51.6 81 7.0
Cerebrovascular disease (430 to 438) 141 36.9 200 17.4
AF indicates atrial fibrillation; CVD, cardiovascular disease.
*Unadjusted rates per 1000 person-years.
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matched with 354 participants without AF, characteristics at
the time of matching were similar (Table 7). The unadjusted
days per year in the hospital were 8.7 (95% CI 7.1 to 10.7) and
2.3 (95% CI 1.7 to 3.1) for participants with and without AF,
respectively (rate ratio 3.87, 95% CI 2.77 to 5.42) (Table 8). In
the outpatient setting, the unadjusted annual rate of utilization
was 47.1 (95% CI 43.3 to 51.3) and 21.8 (95% CI 19.5 to 24.3)
for those with and without AF, respectively (rate ratio 2.18, 95%
CI 1.89 to 2.50). Based on the primary diagnosis code in the
propensity score–matched model, for those with AF compared
with those without AF, the rate ratio for days hospitalized per
year for other CVD–related reasons was 3.82 (95% CI 2.21 to
6.59) and for non-CVD–related reasons was 4.19 (95% CI 2.86
to 6.12) (Table 9). The propensity score–matched rate ratio for
other CVD–related reasons in the outpatient setting was 2.55
(95% CI 2.13 to 3.05) for those with and those without AF; for
non-CVD–related reasons, the propensity score–matched rate
ratio was 1.89 (95% CI 1.64 to 2.18). Similar secular trends in
healthcare utilization were observed. The impact of AF on
inpatient (MedPAR) utilization increased over time (P=0.004),
but there was no effect modification of the association between
AF and outpatient utilization (P=0.16) (data not shown).
Discussion
In this sample of AF patients and matched controls from a
community-based prospective study, rates of both inpatient
(MedPAR) and outpatient healthcare utilization were substan-
tially higher among participants with AF compared with those
matched with cases and without AF. In both the inpatient and
outpatient settings, healthcare utilization was greatest for
non-CVD–related reasons for those with and those without
AF; however, the magnitude of the difference in utilization
between those with and without AF was greatest for other
CVD–related reasons. Our findings underscore the high
prevalence of cardiovascular comorbidities, particularly HF,
triggering healthcare utilization among AF patients. At the
time of AF diagnosis or matching, HF was almost 3 times
more prevalent in AF patients compared with matched
participants. The prevalence of other comorbidities, including
hypertension, diabetes, coronary heart disease, and low
creatinine-based estimated glomerular filtration rate, were
Figure 2. Multivariable adjusted rate ratios of inpatient (MedPAR)
and outpatient healthcare utilization by year of matching comparing
participants with and without atrial fibrillation. Diamonds represent
rate ratios for inpatient (MedPAR) utilization. Squares represent rate
ratios for outpatient utilization. *Rate ratios adjusted for matching
criteria—age (2 years), sex, race, and field center—and for high
school graduate, current smoking, current drinking, body mass
index, hypertension, antihypertensive medication, diabetes mellitus,
estimated glomerular filtration rate, forced expiratory volume in 1
second, and prior heart failure and coronary heart disease. MedPAR
indicates Medicare Provider Analysis and Review.
Table 7. Characteristics of Propensity Score Matched
Participants by AF Status Based on Closest Atherosclerosis
Risk in Communities Study Examination Preceding AF
Diagnosis or Matching
AF (n=354) No AF (n=354) P Value
Propensity score 0.230.06 0.230.06 0.78
Age at matching, y 73.64.8 73.64.7
Women 48.9 48.9
Black 11.6 11.6
High school graduate 78.8 81.1 0.45
Current smoker 9.9 13.6 0.13
Current drinker 50 52.8 0.45
Body mass index, kg/m2 28.34.9 28.34.9 0.85




Diabetes mellitus 15.3 13.3 0.45
Total cholesterol, mg/dL 200.334.3 201.736.9 0.6
LDL-c, mg/dL 124.131.5 125.533.1 0.57
HDL-c, mg/dL 46.019.6 46.418.8 0.83








Heart failure 1.7 0.9 0.31
Coronary heart disease 5.7 4.8 0.61
Categorical variables presented as percentage; continuous variables presented as
meanSD. P values comparing the distributions of age, sex, and race are not presented
because these variables were used to match participants without AF to those with AF,
ensuring balance in their distribution. AF indicates atrial fibrillation; eGFRcreat, creatinine-
based estimated glomerular filtration rate; FEV1, forced expiratory volume in 1 second;
HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
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significantly higher among AF patients compared with the
non-AF matched controls. Although AF has long been thought
of as an electrical conduction problem, the high prevalence of
cardiovascular comorbidities and the higher rate of healthcare
utilization among those with AF, especially for other CVD–
related reasons, provide evidence that AF should not be
considered as just an electrical problem but rather as a
marker of underlying vascular disease and overall cardiovas-
cular risk. A Danish nationwide study reported that, within
each age group, hospitalization rates for CVD and non-CVD
admissions were higher among those with AF compared with
those without AF.27 Furthermore, a 30-year follow-up of
Olmsted County, Minnesota, residents diagnosed with lone
AF, considered to be purely an electrical conduction problem,
revealed that those with AF had a slightly elevated risk of
developing HF or a cerebrovascular event compared with the
age- and sex-matched Minnesota population.28 Moreover, in a
contemporary anticoagulated AF population, 90% of deaths
were related to reasons other than stroke,29 corroborating the
impact of cardiovascular comorbidities on mortality reported
from the AFFIRM trial30 and the Atrial Fibrillation and
Congestive Heart Failure (AF-CHF) trial.31 In the present
study, the associations between AF and inpatient (MedPAR)
and outpatient healthcare utilization remained significant but
were attenuated after adjusting for comorbidities. The overall
adjusted rate ratio for days hospitalized because of other
CVD–related reasons was 4.58 (95% CI 3.41 to 6.16) among
those with AF compared with those without AF; the
corresponding adjusted rate ratio for outpatient utilization
was 2.46 (95% CI 2.24 to 2.70). These findings suggest that it
Table 8. Association of AF With Inpatient (MedPAR) and Outpatient Healthcare Utilization Among Propensity Score–Matched
Atherosclerosis Risk in Communities Study Participants
AF (n=354) No AF (n=354) Rate Ratio
Follow-up, years (meanSD) 4.33.7 4.13.6
Inpatient (MedPAR) utilization, days
Per person, median (IQR)* 7 (0 to 25) 0 (0 to 6) 3.87(2.77 to 5.42)
Rate† 8.7 (7.1 to 10.7) 2.3 (1.7 to 3.1)
Outpatient utilization‡
Per person, median (IQR)* 128 (47 to 226) 43 (12 to 108) 2.18 (1.89 to 2.50)
Rate† 47.1 (43.3 to 51.3) 21.8 (19.5 to 24.3)
AF indicates atrial fibrillation; IQR, interquartile range; MedPAR, Medicare Provider Analysis and Review.
*During follow-up.
†Rate per year.
‡Outpatient utilization defined as unique claims per date of service.
Table 9. Primary Reason for Inpatient (MedPAR) and Outpatient Healthcare Utilization Among Propensity Score–Matched
Atherosclerosis Risk in Communities Study Participants Stratified by AF Status
AF (n=354) No AF (n=354) Rate Ratio
Inpatient (MedPAR) utilization, days
Rates*
AF related 0.2 (0.1 to 0.3) — —
Other CVD related 2.0 (1.4 to 2.8) 0.7 (0.4 to 1.1) 3.82 (2.21 to 6.59)
Non-CVD related 6.5 (5.1 to 8.3) 1.6 (1.2 to 2.2) 4.19 (2.86 to 6.12)
Outpatient utilization†
Rates*
AF related 4.7 (3.9 to 5.5) 0.01 (0.00 to 0.03) —
Other CVD related 6.8 (6.0 to 7.5) 2.9 (2.5 to 3.4) 2.55 (2.13 to 3.05)
Non-CVD related 35.5 (32.3 to 38.9) 18.8 (16.8 to 21.1) 1.89 (1.64 to 2.18)
AF indicates atrial fibrillation; CVD, cardiovascular disease; MedPAR, Medicare Provider Analysis and Review.
*Rates are days per year for inpatient (MedPAR) data and number of unique claims per date of service per year for outpatient claims.
†Outpatient utilization defined as unique claims per date of service.
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is not just the presence of AF that causes healthcare
utilization but also the company it keeps—hypertension,
diabetes mellitus, HF, and coronary heart disease—contrib-
uting, in part, to higher rates of healthcare utilization among
AF patients. Our results underscore the importance of
adequate management and control of these comorbidities.
Despite the attenuation with adjustment for comorbidities,
healthcare utilization remained substantially greater among
those with AF, indicating considerable additional medical
demand among this subset of the population.
Despite published disparities in AF treatment between men
and women32–34 and between white and black
patients,17,18,35 our study did not identify a differential impact
of AF by sex or race on inpatient (MedPAR) or outpatient
utilization; however, the numbers of women and black
participants with AF were small and were from a small
number of geographic areas, so it is possible that our study
was underpowered to detect a difference.
There was evidence of a secular trend in the association of
AF with both inpatient (MedPAR) and outpatient utilization;
the impact of AF on healthcare utilization increased during the
study period. Due to the relatively narrow age range—ARIC
participants were recruited in 1987–1989, when they were
aged 45 to 64 years—it is difficult to separate secular trends
from the increased risk of disease with age. It is possible that
the results from the sensitivity analysis reflect comparatively
more frailty among those with AF compared with those
without AF in the later period of the follow-up. Increased
awareness and treatment of AF over time or greater emphasis
on quality metrics could explain the trend of increased impact
of AF on healthcare utilization. The present study did not have
data to address these potential explanations.
Thematched propensity score results reinforced the primary
findings. In this sensitivity analysis, the comorbidity burden was
similar at the time of matching among those with AF compared
with those without AF. Still, the rates of inpatient (MedPAR) and
outpatient utilization were higher among participants with AF
compared with those free of AF, suggesting that the differences
in utilization were not due to differences in comorbidities at the
time of matching. This study has several limitations. The CMS
Medicare files for ARIC analysis did not contain line items;
therefore, multiple claims for the same date of service with
identical diagnosis codes could not be included in this study.
Without the line items, it is impossible to know whether the
claims are for multiple services (laboratory, x-ray, physician)
related to the same condition or for the same claim submitted
multiple times. By excluding claims with identical diagnostic
codes for the same date of service, our estimates are
conservative and, if anything, underestimate healthcare utili-
zation. In addition, our study had to be restricted to FFS
Medicare enrollment windows because Medicare Advantage
plans are not required to submit claims on their beneficiaries.
Although exclusion of Medicare Advantage enrollment windows
limits the generalizability of study findings, the results are
applicable to the FFS population. A weakness of the ARIC study
is that it includes white and black participants from only 3 and 2
communities, respectively, andmight not be generalizable to all
white and black patients in the United States. This study is
innovative in its use of a community-based prospective study to
identify the study sample; however, it is crucial to consider
these threats to generalizability and not mistakenly project the
findings too broadly. Moreover, because of small numbers of
diagnosed AF, the power to detect significant effect modifica-
tion by sex or race was low; among women and black
participants, 413 and 123 participants were diagnosed with
AF, respectively. Consequently, we described healthcare
utilization by subgroups but cannot make conclusive state-
ments about similarities or differences by sex or race.
Nevertheless, this study is the first to provide sex- and race-
specific data on inpatient and outpatient utilization.
This study also has several strengths. Claims data contain
little information on clinical characteristics because their
primary purpose is reimbursement. In this study, data
collected as part of the ARIC study examinations were linked
to Medicare data; consequently, information unavailable in
claims data, such as detailed and validated demographic,
behavioral, and comorbid conditions measured using stan-
dardized methodology, were present and included in analyses.
Second, prior research on AF did not study outpatient
healthcare utilization.12,13 Furthermore, previous studies were
conducted in a predominately white population13 or did not
consider differences by sex or race.12,13 In response to the
noted gaps in the literature, we described overall healthcare
utilization among participants with and without AF and sex-
and race-specific utilization for both inpatient (MedPAR) and
outpatient services.
In conclusion, this study provides evidence of the burden
of AF healthcare utilization. The results highlight that AF is not
just an electrical problem and that treatment guidelines
should incorporate assessment of overall cardiovascular risk
and provide recommendations on comprehensive manage-
ment of the patient. Participants with AF had greater
underlying vascular disease and spent significantly more days
hospitalized and seeking outpatient care than similar partic-
ipants without AF. The magnitude of the difference in
utilization between those with and without AF was greatest
for other CVD–related reasons and emphasizes the need to
treat the underlying vascular disease in addition to rhythm or
rate management among those with AF.
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